Diakonos Oncology Announces First Patients Dosed in Phase 1/2 DOC-RM Study of DOC1021 in Refractory Melanoma
· manilatimes.net
First patients dosed at City of Hope and the University of Alabama at BirminghamDOC-RM recently featured as a Trial-in-Progress presentation at the 2026 ASCO Annual MeetingFDA Fast Track designation granted for unresectable or metastatic cutaneous melanoma Outpatient treatment approach without lymphodepleting chemotherapy or high-dose IL-2Initial safety, biomarker and clinical activity results anticipated in Q4 2026 HOUSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced that the first patients have been dosed in DOC-RM, its Phase 1/2 clinical study evaluating DOC1021 (dubodencel) in patients with refractory melanoma, at City of Hope in Duarte, California, and the University of Alabama at Birmingham (UAB).
First patients dosed at City of Hope and the University of Alabama at Birmingham
DOC-RM recently featured as a Trial-in-Progress presentation at the 2026 ASCO ...